Evidence map›Paper›PMID 37397490›Full record

ArticleFrontiers in pharmacology2023

Identification of potential quality markers of Zishen Yutai pill based on spectrum-effect relationship analysis.

Sijia Wu, Qiuling Huang, Feiya Sheng, Lele Zhang, Liang Zou, Lele Yang, Jiliang Cao, Xiufei Pang, Na Ning, Peng Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sijia WuState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China.
Qiuling HuangGuangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd., Guangzhou, Guangdong, China.
Feiya ShengSchool of Basic Medical Sciences, Chengdu University, Chengdu, China.
Lele ZhangSchool of Basic Medical Sciences, Chengdu University, Chengdu, China.
Liang ZouSchool of Food and Biological Engineering, Chengdu University, Chengdu, China.
Lele YangState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China.
Jiliang CaoCollege of Pharmacy, Shenzhen Technology University, Shenzhen, China.
Xiufei PangGuangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd., Guangzhou, Guangdong, China.
Na NingGuangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd., Guangzhou, Guangdong, China.
Peng LiState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

in vitroin vivooffline two-dimensional liquid chromatography-mass spectrometryquality markersspectrum–effect relationshiptraditional Chinese medicineZishen Yutai pill

Identifiers

PMID37397490
PMCPMC10311498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.